Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSFX Switch Therapy vs Ampicillin/Sulbactam in Older Patients with Community-Acquired Pneumonia
jRCTs071250072Recruiting
- Sponsor
- Kyorin Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in community-acquired pneumonia (CAP) comparing Lascufloxacin Switch Therapy Group with Ampicillin/Sulbactam Intravenous Group (2 arms). Primary endpoint: Clinical cure rate at test-of-cure. Started Nov 2025; status: recruiting.
02
Drugs
lascufloxacinampicillin + sulbactam
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on jRCTs071250072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071250072.